Flower


WHO Pre Qualifies BE’s Typhoid Conjugate Vaccine

by The Welthi Bureau, December 11th, 2020

who pre qualifies be’s typhoid conjugate vaccine
 Image used for representational purpose only

Hyderabad (India), December 11, 2020: (BE), a Hyderabad-based vaccines and pharmaceutical company, today announced that its Typhoid Conjugate Vaccine (TCV) has been pre-qualified by the World Health Organisation (WHO). With this pre-qualification, BE became one of two pre-qualified suppliers of TCV to the UN agencies.

 

BE’s TCV is a single-dose injectable vaccine, which can be administered to children from 6 months of age to adults up to the age of 45 and it is formulated with Vi polysaccharide conjugated to a carrier protein (CRM197). The Vi polysaccharide antigen used in BE’s TCV is derived from C. freundii, which is a non-pathogenic source (BSL 1 organism), compared to virulent Salmonella Typhi used by other manufacturers, and the carrier protein used for conjugation is a non-toxic CRM197 protein locally developed by BE through in-house R&D effort. Clinical studies conducted in India have shown that the safety and immunogenicity profiles of this vaccine are comparable with those of the other WHO pre-qualified TCV. BE offers this vaccine as single-dose and multi-dose vials for ease of administration.

 

The vaccine was developed in collaboration with the GSK Vaccines Institute for Global Health (GVGH), based in Siena, Italy, which first developed the vaccine strain and transferred the technology to BE in 2013. BE has further developed the vaccine, including manufacturing process optimization and scale up, pre-clinical studies and comprehensive clinical trials for Phase I, II/III in India. Today, this vaccine is being manufactured in BE’s GMP manufacturing facilities in Hyderabad, India.

 

“This is a remarkable accomplishment and a significant milestone in the journey of our vaccines. I am delighted that we have been able to produce a new WHO pre-qualified vaccine. We believe that every year this vaccine would save about 1.5 Lakh people worldwide,” said Ms. Mahima Datla, Managing Director, Biological E. Limited.

 “GSK, through its R&D efforts at GVGH, is proud to have played an essential role in providing technologies to Biological E for their Typhoid Conjugate Vaccine (TCV),” said Francesco Berlanda-Scorza, GVGH Director. For more than a decade, GVGH has been advancing vaccines for under-recognised diseases, and as a result of an innovative partnership with Biological E to develop this vaccine, and TCV prequalification by WHO, many more children will have access to a much needed intervention for prevention of typhoid fever.”

In March 2020, BE received approval from India's health regulators to authorise and market a new TCV (BE’s product TYPHIBEV) for infants, children and adults from 6 months.  

This pre-qualification from WHO allows BE to make a significant contribution to unmet public health needs in developing countries by helping to protect children against typhoid and helping to secure the supply of vaccines against typhoid.

 

 

      About Biological E. Limited

 

Biological E. Limited (BE), a Hyderabad-based Pharmaceuticals & Biologics Company founded in 1953, is the first private sector biological products company in India and the first pharmaceutical company in Southern India. BE develops, manufactures and supplies vaccines and therapeutics. BE supplies its vaccines to over 130 countries and its therapeutic products are sold in India and the USA. BE currently has 8 WHO-prequalified vaccines in its portfolio.

In recent years, BE has embarked on new initiatives for organisational expansion such as developing generic injectable products for the regulated markets, exploring synthetic biology and metabolic engineering as a means to manufacture APIs sustainably and developing novel vaccines for the global market.

    


 Disclaimer: Welthi.com does not guarantee any specific results as a result of the procedures mentioned here, and the results may vary from person to person. Read more
Ambassador of Republic of Estonia, Ms. Katrin KIVI visits MaxiVision super speciality eye hospitals

Ambassador of Republic of Estonia, Ms. Katrin ...

Ambassador of Republic of Estonia, Ms. Katrin KIVI...
 SLG Hospitals launch Sakhi an empowerment initiative for health and wellbeing of women

SLG Hospitals launch Sakhi an empowerment ...

SLG Hospitals launch Sakhi an empowerment initiat...
Alarming rise in child obesity in India, has serious repercussions for future, caution Medical Specialists

Alarming rise in child obesity in India, has ...

Alarming rise in child obesity in India, has serio...
RARE HONOUR FOR CITY BASED CARDIAC SURGEON DR. LOKESWARA RAO SAJJA OF STAR HOSPITALS ELECTED AS JUNIOR VICE PRESIDENT OF INDIAN ASSOCIATION OF CARDIOVASCULAR THORACIC SURGEONS

RARE HONOUR FOR CITY BASED CARDIAC SURGEON DR. ...

RARE HONOUR FOR CITY BASED CARDIAC SURGEON DR. LOK...
A five year old got New life KIMS Hospital Doctor saved the boy life performing a critical bone marrow transplantation

A five year old got New life KIMS Hospital ...

A five year old got New life KIMS Hospital Doctor ...
PROFICIENT RADIOLOGIST AT OLIVE HOSPITALS DECODES A MISDIAGNOSED CASE Identified and Detected a Rare Brain Tumor

PROFICIENT RADIOLOGIST AT OLIVE HOSPITALS ...

PROFICIENT RADIOLOGIST AT OLIVE HOSPITALS DECODES ...
Wockhardt Hospital, Mira Road conducts free general health check-up for cops

Wockhardt Hospital, Mira Road conducts free ...

Wockhardt Hospital, Mira Road conducts free genera...
SuVitas Launches Bangalore’s First Dedicated Transition Care Facility

SuVitas Launches Bangalore’s First Dedicated ...

Catering to a need for post critical care that has...
Itermittent Fasting: The How s and Why's

Itermittent Fasting: The How s and Why's

Intermittent Fasting is the latest global fitness ...
Eyes show you the world

Eyes show you the world

With increasing rate of air pollution, the ways it...
Healthcare receives major limelight in General Budget 2018-19

Healthcare receives major limelight in General ...

Healthcare has been a core segment in every develo...